Stifel raises price target on WELL Health Technologies

Nick Waddell · Founder of Cantech Letter
June 3, 2026 at 8:49am ADT 2 min read
Last updated on June 3, 2026 at 8:49am ADT
WELL stock

Stifel analyst Justin Keywood says WELL Health Technologies’ (WELL Health Technologies Stock Quote, Chart, News, Analysts, Financials TSX:WELL) $160-million imaging-clinic acquisition expands its leading market position and should create room for efficiencies.

In a June 2 update, Keywood maintained his “buy” rating on WELL and raised his target to $8.25 from $8.00.

WELL announced the acquisition of about 15 imaging diagnostics and procedure services clinics through two Ontario and Quebec transactions, Ontario Imaging Diagnostics and an approximately 66% interest in UnionMD. The acquisitions include $115-million of upfront consideration and generate about $90-million in revenue and $22-million in Adjusted EBITDA, implying a margin of about 25%.

Keywood estimated the purchase multiple at a favourable seven to eight times EBITDA. He said the deal would lift WELL Canada to more than $800-million in sales and more than $100-million in EBITDA, reaching that level three quarters earlier than previously guided. WELL also expects to exceed its 2026 guidance of $175-million to $185-million in Adjusted EBITDA.

“We view the transaction as significant and positive as diagnostics assets are Healthcare infrastructure and difficult to procure, provided the high-margin nature, limited licenses available and secular tailwinds, including from system strain and substantial wait-lists,” Keywood said.

Keywood said WELL’s 2021 MyHealth acquisition showed about 500 basis points of margin expansion within three years, helped by referrals from WELL primary-care doctors into diagnostics. He said the new acquisitions could offer similar benefits as WELL integrates them with its existing primary-care network.

With the acquisitions, Keywood raised his 2026 revenue estimate to $1.591-billion from $1.551-billion and his Adjusted EBITDA estimate to $185.0-million from $180.3-million, putting his EBITDA forecast at the top end of guidance.

“However, we leave room for upward revisions as the performance of the acquired clinics and synergy potential with the existing primary care network via referrals becomes more clear in coming quarters,” he said.

Keywood estimates the upfront consideration will lift WELL’s pro forma next-12-month net debt to Adjusted EBITDA ratio to 2.9 times from 2.4 times at the end of Q1 2026.

WELL trades at 1.3 times 2026 EV/sales, compared with U.S. virtual care and health-tech peers at an average of 2.1 times to 2.7 times.

“We believe as WELL executes on favourable guidance, with performance buoyed by seemingly nicely accretive transactions adding scale to the Canadian clinic network, shares should re-rate higher,” Keywood said.

Disclosure: Nick Waddell owns shares of WELL Health and the company is an annual sponsor of Cantech Letter.

 

-30-

✖

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Author photo

Nick Waddell

Founder of Cantech Letter

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.